Please note that maintenance work is scheduled between 4 AM and 5 AM - CET.
During this time, you may experience reduced performance.
Thanks for your patience.
in (world ranking)
Serafin Morales
Oncology — Hospital Universitari Arnau de Vilanova, Spain
Serafin Morales
Joined Jun 2026
Hospital Universitari Arnau de Vilanova · Oncology
Top 1% Worldwide expert in Breast Neoplasms, Breast Diseases
Phase Ib III Study of Capivasertib CDK4 6 Inhibitors Fulvestrant as Treatment for Advanced Metastatic HR HER2 Breast Cancer (CAPItello 292) 2023-504997-39-00 — genes, epidermal growth factor, fulvestrant, growth, breast neoplasms, neoplasms, hormones, receptors, growth factor, breast, therapeutics
Phase 3
Active not recruiting
2021
NoLEEta Phase III non inferiority trial of chemotherapy de escalation in hormone receptorpositive Her2 negative intermediate risk early breast cancer treated with Ribociclib (LEE 011) in the adjuvant setting 2025-520979-13-00 — breast neoplasms, neoplasms, drug therapy, hormones, chemotherapy, adjuvant, breast, chemotherapy
Phase 3
Not yet recruiting
2025
A proof of concept study to evaluate treatments efficacy by monitoring Minimal Residual Disease using ctDNA in HR positive HER2 negative early breast cancer population 2023-505661-89-00 — epidermal growth factor, growth, breast neoplasms, neoplasms, hormones, proof of concept study, receptors, growth factor, breast, neoplasm, residual, therapeutics
Phase 2
Recruiting
2024
First in Human Study of OKI 219 Alone and in Combination with Other Therapies in Patients with Solid Tumors Breast Cancer 2023-508435-31-00 — breast neoplasms, neoplasms, breast, therapeutics
Phase 1
Recruiting
2024
A Randomized Multicenter Placebo controlled Phase 3 study to Evaluate the Efficacy and Safety of HER2 neu Peptide GLSI 100 (GP2 GM CSF) in HER2 neu Positive Subjects with Residual Disease or High Risk PCR after both Neoadjuvant and Postoperative Adjuvant Trastuzumab based Therapy (FLAMINGO 01) 2023-504323-25-01 — granulocyte-macrophage colony-stimulating factor, safety, breast neoplasms, polymerase chain reaction, neoplasms, breast, therapeutics, trastuzumab
To provide the best experience, we use technologies such as cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Failure to consent or withdrawal of consent may adversely affect certain features and functions.
Functional
Always active
Storage or technical access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of transmitting a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
Storage or technical access used exclusively for statistical purposes.The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
Storage or technical access is necessary to create user profiles in order to send advertisements, or to track the user on a website or on several websites with similar marketing purposes.